Report: NHL Drug Market Will Nearly Double to More Than $10 Billion by 2022
Rituximab and new premium-priced agents drive annual growth (October 28)
Decision Resources, a research and advisory firm located in Burlington, Mass., finds that, from 2012 to 2022, the launch of five new premium-priced agents — ibrutinib (Johnson & Johnson/Janssen/ Pharmacyclics), idelalisib (Gilead Sciences), obinutuzumab (Roche/Genentech), lenalidomide (Revlimid, Celgene), and everolimus (Afinitor, Pfizer) — together with the continued use of rituximab (Rituxan/MabThera, Roche/Genentech) will fuel more than 6% annual growth in the non-Hodgkin’s lymphoma (NHL) drug market.
In the U.S., Europe, and Japan, sales will exceed $10 billion in 2022, with the kinase inhibitors ibrutinib and idelalisib comprising more than one-fifth of market share. These two agents will launch as treatments for multiple NHL subpopulations, and their use in combination with existing therapies, as well as monotherapies, will ensure that they will significantly add to the overall size of the market, the report predicts. The anticipated approval of lenalidomide in the diffuse large B-cell lymphoma maintenance setting will also trigger significant market growth.
The report also finds that sales of rituximab dominate the current market and will continue to do so through 2022, regardless of the entry of biosimilars. Bendamustine (Treanda, Cephalon/Teva), a cytotoxic chemotherapy that is becoming increasingly entrenched in the treatment of NHL, will continue to experience an increase in use across most NHL subpopulations, but its sales will decline as a result of generic competition.
“New therapies entering the market will change the way NHL patients are treated by 2022,” said analyst Dana Gheorghe, PhD. “Of particular interest are the entries of the kinase inhibitors ibrutinib and idelalisib, which are poised to have a tremendous impact on the treatment of NHL patients, especially those with relapsed/refractory chronic lymphocytic leukemia and follicular lymphoma, but also mantle cell lymphoma. The anticipated approval of obinutuzumab will also impact how some NHL patients are managed, as the drug has been shown to be more efficacious than rituximab in certain subpopulations.”
Source: Decision Resources; October 28, 2013.